Posted by Michael Wonder on 03 Mar 2025
Amyloid cardiomyopathy drug Vyndamax to get health insurance from March
28 February 2025 - Vyndamax (tafamidis), a transthyretin amyloid cardiomyopathy medicine that has experienced difficulties getting on the health insurance list due to its high cost will receive insurance benefits from 1 March 2025, significantly easing the burden of treatment costs for Korean patients.
The Ministry of Health and Welfare held the Health Insurance Policy Review Committee on Thursday and approved the proposal to reimburse Vyndamax.
